A clinician's guide to correct cost-effectiveness analysis: Think incremental not average

Canadian Journal of Psychiatry

Volumn 53, Issue 4, 2008, Pages 267-274

  Hoch, Jeffrey S ^a,c   Dewa, Carolyn S ^b  

^a ST MICHAEL'S HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c Centre for Research on Inner City Health   (Canada)

Author keywords

Cost effectiveness analysis; Incremental cost effectiveness ratio; Mental health economics; Net benefit regression

Indexed keywords

HISTAMINE H2 RECEPTOR ANTAGONIST; NEUROLEPTIC AGENT; OMEPRAZOLE;

COST EFFECTIVENESS ANALYSIS; DEPRESSION; DRUG COST; ECONOMIC ASPECT; HEALTH CARE COST; HUMAN; MEDICAL DECISION MAKING; MENTAL HEALTH CARE; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; REVIEW; SCHIZOPHRENIA;

EID: 45249109772     PISSN: 07067437     EISSN: 14970015     Source Type: Journal    
DOI: 10.1177/070674370805300408     Document Type: Review

References (54)

1. Eddy DM. Oregon's methods. Did cost-effectiveness analysis fail? JAMA. 1991;266:2135-2141.
2. Laupacis A. Incorporating economic evaluations into decision-making: the Ontario experience. Med Care. 2005;43:15-19.
3. Hoch JS, Dewa CS. An introduction to economic evaluation: what's in a name? Can J Psychiatry. 2005;50:159-166.
4. Polsky D, Doshi JA, Bauer MS, et al. Clinical trial-based cost-effectiveness analyses of antipsychotic use. Am J Psychiatry. 2006;163:2047-2056.
5. Evers SM, Van Wijk AS, Ament AJ. Economic evaluation of mental health care interventions. A review. Health Econ. 1997;6:161-177.
6. Udvarhelyi IS, Colditz GA, Rai A, et al. Cost-effectiveness and cost-benefit analyses in the medical literature. Are the methods being used correctly? Ann Intern Med. 1992;116:238-244.
7. Gerard K. Cost-utility in practice: a policy maker's guide to the state of the art. Health Policy. 1992;21:249-279.
8. Molken MP, Van Doorslaer EK, Rutten FF. Economic appraisal of asthma and COPD care: a literature review 1980-1991. Soc Sci Med. 1992;35:161-175.
9. Ganiats TG, Wong AF. Evaluation of cost-effectiveness research: a survey of recent publications. Fam Med. 1991;23:457-462.
10. Doshi JA, Glick HA, Polsky D. Analyses of cost data in economic evaluations conducted alongside randomized controlled trials. Value Health. 2006;9:334-340.
11. Marks RD, Richter JE, Rizzo J, et al. Omeprazole versus H2-receptor antagonists in treating patients with peptic stricture and esophagitis. Gastroenterology. 1994;106:907-915.
12. Harris RA, Nease RF: Economic heartburn: average cost-effectiveness and gastroesophageal reflux disease. Gastroenterology. 1995;108:303-304.
13. Marks RD, Richter JE, Rizzo J. Reply to: omeprazole versus H2-receptor antagonists in treating patients with peptic stricture and esophagitis. Gastroenterology. 1995;108:304.
14. Doubilet P, Weinstein MC, McNeil BJ. Use and misuse of the term "cost effective" in medicine. N Engl J Med. 1986;314:253-256.
15. Provenzale D, Lipscomb J. Cost-effectiveness: definitions and use in the gastroenterology literature. Am J Gastroenterol. 1996;91:1488-1493.
16. Zarnke KB, Levine MA, O'Brien BJ: Cost-benefit analyses in the health-care literature: don't judge a study by its label. J Clin Epidemiol. 1997;50:813-822.
17. Marshall JK, O'Brien BJ. Cost and cost-effectiveness: consistent terminology is needed. Am J Gastroenterol. 1999;94:1108-1109.
18. Neumann PJ, Stone PW, Chapman RH, et al. The quality of reporting in published cost-utility analyses, 1976-1997. Ann Intern Med. 2000;132:964-972.
19. Petitti DB. Meta-analysis, decision analysis, and cost-effectiveness analysis: methods for quantitative synthesis in medicine. New York (NY): Oxford University Press; 1994.
20. Drummond MF. Methods for the economic evaluation of health care programmes. New York (NY): Oxford University Press; 2005.
21. Gold MR, Siegel JE, Russell LB, et al. Cost-effectiveness in health and medicine. New York (NY): Oxford University Press; 1996.
22. Sloan FA: Valuing health care: costs, benefits, and effectiveness of pharmaceuticals and other medical technologies. New York (NY): Cambridge University Press; 1995.
23. Detsky AS, Naglie IG. A clinician's guide to cost-effectiveness analysis. Ann Intern Med. 1990;113:147-154.
24. Laska EM, Meisner M, Siegel C. Statistical inference for cost-effectiveness ratios. Health Econ. 1997;6:229-242.
25. Laska EM, Meisner M, Siegel C. The usefulness of average cost-effective ratios. Health Econ. 1997;6:497-504.
26. Canadian Coordinating Office for Health Technology Assessment. Guidelines for economic evaluation of pharmaceuticals, Canada. Ottawa (ON): Canadian Coordinating Office for Health Technology Assessment; 1997.
27. Briggs A, Fenn P. Trying to do better than average: a commentary on 'statistical inference for cost-effectiveness ratios.' Health Econ. 1997;6:491-495.
28. Canadian Expert Drug Advisory Committee [Internet]. Ottawa (ON): Canadian Agencies for Drugs and Technologies in Health [cited 2007 Jun 8]. Available from: http://www.cadth.ca/index.php/en/cdr/committees/cedac.
29. Common Drug Review [Internet]. Ottawa (ON): Canadian Agencies for Drugs and Technologies in Health [cited 8 June 2007]. Available from: http://www.cadth.ca/index.php/en/cdr.
30. Neuhauser D, Lweicki AM. What do we gain from the sixth stool guaiac? N Engl J Med. 1975;293:226-228.
31. Getzen TE. Health economics: fundamentals and flow of funds. New York (NY): John Wiley & Sons; 1997.
32. Hershey JC, Asch DA, Jepson C, et al. Incremental and average cost-effectiveness ratios: will physicians make a distinction? Risk Anal. 2003;23:81-89.
33. Stinnett AA, Mullahy J. Net health benefits: a new framework for the analysis of uncertainty in cost-effectiveness analysis. Med Decis Making. 1998;18:S68-80.
34. Tambour M, Zethraeus N, Johannesson M. A note on confidence intervals in cost-effectiveness analysis. Int J Technol Assess Health Care. 1998;14:467-471.
35. Hoch JS, Briggs AH, Willan AR. Something old, something new, something borrowed, something blue: a framework for the marriage of health econometrics and cost-effectiveness analysis. Health Econ. 2002;11:415-430.
36. Hoch JS, Smith MW. A guide to economic evaluation: methods for cost-effectiveness analysis of person-level data. J Trauma Stress. 2006;19:787-797.
37. Hoch JS, Rockx MA, Krahn AD. Using the net benefit regression framework to construct cost-effectiveness acceptability curves: an example using data from a trial of external loop recorders versus Holter monitoring for ambulatory monitoring of "community acquired" syncope. BMC Health Serv Res. 2006;6:68.
38. Fenwick E, Marshall DA, Levy AR, et al. Using and interpreting cost-effectiveness acceptability curves: an example using data from a trial of management strategies for atrial fibrillation. BMC Health Serv Res. 2006;6:52.
39. van Hout BA, Al MJ, Gordon GS, et al. Costs, effects and C/E-ratios alongside a clinical trial. Health Economics. 1994;3:309-319.
40. Lothgren M, Zethraeus N. Definition, interpretation and calculation of cost-effectiveness acceptability curves. Health Economics. 2000;9:623-630.
41. Fenwick E, Claxton K, Sculpher M. Representing uncertainty: the role of cost-effectiveness acceptability curves. Health Econ. 2001;10:779-787.
42. Hoch JS, Blume JD. Measuring and illustrating statistical evidence in a cost-effectiveness analysis. J Health Econ. Forthcoming.
43. Han SH, Martin P, Edelstein M, et al. Conversion from intravenous to intramuscular hepatitis B immune globulin in combination with lamivudine is safe and cost-effective in patients receiving long-term prophylaxis to prevent hepatitis B recurrence after liver transplantation. Liver Transpl. 2003;9:182-187.
44. Wilkins JJ, Folb PI, Valentine N, et al. An economic comparison of chloroquine and sulfadoxine-pyrimethamine as first-line treatment for malaria in South Africa: development of a model for estimating recurrent direct costs. Trans R Soc Trop Med Hyg. 2002;96:85-90.
45. Han SH, Ofman J, Holt C, et al. An efficacy and cost-effectiveness analysis of combination hepatitis B immune globulin and lamivudine to prevent recurrent hepatitis B after orthotopic liver transplantation compared with hepatitis B immune globulin monotherapy. Liver Transpl. 2000;6:741-748.
46. Vergnenegre A, Perol M, Pham E. Cost analysis of hospital treatment - two chemotherapic regimens for non-surgical non-small cell lung cancer. GFPC (Groupe Francais Pneumo Cancerologie). Lung Cancer. 1996;14:31-44.
47. Lehman AF, Dixon L, Hoch JS, et al. Cost-effectiveness of assertive community treatment for homeless persons with severe mental illness. Br J Psychiatry. 1999;174:346-352.
48. Sheidow AJ, Bradford WD, Henggeler SW, et al. Treatment costs for youths receiving multisystemic therapy or hospitalization after a psychiatric crisis. Psychiatr Serv. 2004;55:548-554.
49. Lin EC, Yin TJ, Kuo BI, et al. A comparison of effectiveness and cost between two models of care for individuals with schizophrenia living in Taiwan. Arch Psychiatr Nurs. 2001;15:272-278.
50. Ramsey S, Willke R, Briggs A, et al. Good research practices for cost-effectiveness analysis alongside clinical trials: the ISPOR RCT-CEA task force report. Value Health. 2005;8:521-533.
51. Drummond M, Sculpher M. Common methodological flaws in economic evaluations. Med Care. 2005;43:5-14.
52. Torgerson DJ, Spencer A. Marginal costs and benefits. BMJ. 1996;312(7022):35-36.
53. Canadian Agency for Drugs and Technologies in Health. Guidelines for the economic evaluation of health technologies: Canada. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2006.
54. Blades CA, Culyer AJ, Walker A. Health service efficiency: appraising the appraisers - a critical review of economic appraisal in practice. Soc Sci Med. 1987;25:461-472.